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Table 1
Multivariate OS Analysis
Total Cohort HR
95% CI P
50-59 Years
HR 95% CI P
60-73 Years
HR 95% CI P
STANDARD
VARIABLES
Age >60 1.83 1.26-
2.65
.001
HCT-CI >¼3 1.56 1.07-
2.28
.02 1.50 .88-
2.53
.13 1.72 .99-
2.98
.05
Active Disease 1.31 .90-
1.90
.16 1.54 .92-
2.58
.10 1.27 .71-
2.27
.42
Ablative
Regimen
1.54 1.02-
2.31
.04 2.14 1.24-
3.69
.01 1.07 .54-
2.10
.85
GA VARIABLES
IADL
Impairment
2.38 1.59-
3.56
<.001 1.86 1.07-
3.24
.03 3.25 1.75-
6.05
<.001
Slow Walk
Speed
1.80 1.14-
2.83
.01 1.16 .60-
2.28
.66 3.27 1.68-
6.39
.001
Reduced
Mental
Health
1.67 1.13-
2.48
.01 1.55 .92-
2.62
.10 1.87 1.01-
3.49
.04
Low Albumin 1.52 .94-
2.46
.09 1.23 .57-
2.63
.60 2.62 1.26-
5.47
.01
High CRP 2.51 1.54-
4.09
<.001 1.89 .94-
3.79
.07 3.13 1.52-
6.46
.002
*Each GA measure analyzed separately, adjusting for standard variables
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(age, HCT-CI, conditioning regimen intensity, disease risk).
Results: 203 adults >¼50 years completed GA and under-
went HCT.Mean agewas 59 years (range 50-73); 45% had high
disease risk, 76% received reduced intensity conditioning, and
14% underwent cord blood HCT. With median follow-up of 36
months, IADL limitations (P < 0.0001), slow walk speed (P ¼
0.01), low SF36-MCS (P¼ 0.01), and high CRP (P<0.001) were
signiﬁcantly associated with inferior OS, independent of
standard HCT variables. The prognostic effect of these GA
variables was greater in older recipients (Table 1). We then
created a simple risk score with 1 point for the most prog-
nostic functional measure (IADL impairment) and 1 point for
comorbidity (HCT-CI >¼3). This signiﬁcantly stratiﬁed out-
comes, particularly in those 60 years, such that 2-year OS
was 63%, 29%, and 0% for 0, 1, and 2 points, respectively.
Conclusion: GA measures confer independent prognostic
utility in older HCT recipients, especially in those >¼60
years. Implementation of GA prior to HCT may aid in
appropriate selection of older adults for HCT.
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Background: Recent studies have shown the intravenous
administration of high-dose cyclophosphamide (CY) in the
early post-transplant period to be a strategy for GvHD
prophylaxis in patients with hematologic malignancies who
receive allogeneic marrow grafts from alternative donors.
We evaluated the outcomes of patients who received
HPC-Apheresis products to compare the impact of post-
transplant CY on neutrophil engraftment, hematopoietic
chimerism, and early immune reconstitution in patients who
received post-HSCT CY following haplo-identical (HAP),matched unrelated donor (MUD), andmismatched unrelated
donor (mMUD) grafts vs. with conventional matched related
donor (MRD) graft recipients.
Methods and Results:We transplanted 44 patients (median
age, 49 years; range, 20-72 years) with advanced hemato-
logic malignancies n¼8 (HAP); 14 (MRD); 17 (MUD); 5
(mMUD). All patients received conditioning regimens based
on busulfan or total body irradiation (TBI). High-dose CY
(50mg/kg/day) was administered on days 3 and 4 following
HAP and on day 3 following MUD transplant. Peripheral
blood lymphocyte reconstitution and quantitative T-cell and
myeloid speciﬁc donor chimerism (STR) status was assessed
on post-HSCT days 30 and 60. Mean time to ANC 500 was
12.5 days for MRD, mMUD and MUD graft recipients. HAP
recipients took slightly longer at 15.2 days but not signiﬁ-
cantly different from others. Day +30 median CD3/CD15
chimerism was 82.3+12.4/99.8+0.5 for MRD; 86.7+16.0/
97.6+2.2 for MUD; 87.6+15.3/99.8+0.4 for mMUD; and
98.8+1.8/99.2+1.2 for HAP. Day +30 HAP CD3 chimerism was
signiﬁcantly improved over MRD (p<0.001) but not over
MUD or mMUD. CD15 chimerism did not differ between
groups. Of 30 patients that received CY, 18(60%) and 27(90%)
achieved full (>95%) donor CD3+ and CD15+chimerism by
day +30, respectively vs. 1 (7%) and 12 (86%) in 16 patients
who underwent MRD transplants. Day +30 total T cell
recovery was signiﬁcantly faster in MRD than CY-treated
recipients (p¼0.015) due principally to more robust CD8+ T
cell recovery. CD4 T cell recovery remained incomplete in all
groups through day +100. Recovery of gd T cells did not differ
between groups. Regulatory T cells are virtually absent. NK
cells recover to normal numbers at day +28 in all groups.
Conclusions: Recipients of HAP, MUD andmMUD grafts who
received post-HSCT CY show similar engraftment kinetics as
those who receive MRD grafts with standard immunosup-
pression. T-cell engraftment appears to follow myeloid
engraftment in those who received post-transplant CYand is
generally earlier by day 30 than in MSD graft recipients,
although CD3+CD8+ recovery is greater in MRD recipients
than others. Taken together, HPC-Apheresis is a reasonable
alternative donor graft source when accompanied by post-
HSCT CY-based GvHD prophylaxis.29
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Background: Haploidentical stem cell transplantation
(HaploSCT) using post-transplant cyclophosphamide (PTCY)
has been performed primarily with non-myeloablative con-
ditioning. We are exploring a melphalan-based, myeloa-
blative yet reduced-intensity conditioning (RIC), in an
ongoing phase II clinical trial.
Methods: Outcomes of the ﬁrst 84 pts treated after 01/2009
are reported. 47(56%) pts were males. 74 (88%) pts had their
ﬁrst transplant, 10 (12%) as second transplant. The median
age was 46 years (range 19-67). 57 (67.9%) pts were protocol
